As the issues surrounding participant diversity become better understood globally, more eyes are turning to the next frontier in drug development diversity, equity, and inclusion: the clinical research workforce.
This article outlines the creation and functioning of an advisory board at Janssen intended, in part, to obtain feedback on strategies and solutions intended for patients, with a primary focus on clinical trial design.
We need to build a robust clinical trials ecosystem that provides consistent access to high-quality healthcare professionals and the most appropriate physical and technological infrastructure.
Site staff are treading water as wave after wave of technology complexity crash over their heads. They need a life raft before they drown.
There are steps that compassionate leaders within sponsors, contract research organizations, and study sites can take to ease the impacts of war upon clinical trials and, wherever possible, ensure patients keep participating.